Article Text

Download PDFPDF
Case report
Disappearance of angina attacks after administration of mepolizumab
  1. Koichi Imai and
  2. Hidenobu Ochiai
  1. Traumatology and Acute Critical Medicine, University of Miyazaki Hospital, Miyazaki-shi, Miyazaki, Japan
  1. Correspondence to Dr Koichi Imai; ki5015{at}gmail.com

Abstract

A 75-year-old woman with bronchial asthma and angina presented with dyspnea. She was using nifedipine, nitroglycerin, pranlukast and salmeterol plus fluticasone propionate inhalations. We diagnosed her with severe bronchial asthma. Oral steroids prescribed for the asthma symptoms had only temporary effects. Therefore, we additionally prescribed mepolizumab; the bronchial asthma improved and the angina attacks disappeared. However, after the patient discontinued treatment, the bronchial asthma and angina attacks recurred, which were treated with nitroglycerin. When she returned 12 weeks later, we resumed mepolizumab administration; the bronchial asthma improved and the angina attacks disappeared again. Hence, we concluded that her angina was due to eosinophilia since the angina attacks disappeared with the mepolizumab therapy. Despite limitations such as lack of arterial blood gas data, perfusion scan, gastrointestinal fiberscopy and Aspergillus skin and precipitation tests, we believe that this is the first report to suggest mepolizumab treatment for angina attacks.

  • ischaemic heart disease
  • respiratory system
  • ear, nose and throat/otolaryngology
  • asthma

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors KI and HO managed the case. KI reported the case and wrote the manuscript. All authors approved the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.